## Protocol Section
### Identification Module
**NCT ID:** NCT06428617

**Brief Title:** Fundus Ablation Registry (Gastric Fundus Mucosal Ablation for Weight Loss)

**Official Title:** A Multi-site, Prospective Registry of Patients Undergoing Gastric Fundal Mucosal Ablation at True You Weight Loss

#### Organization Study ID Info
**ID:** RGT-002
#### Organization
**Class:** OTHER
**Full Name:** True You Weight Loss
### Status Module
#### Completion Date
**Date:** 2028-06

**Type:** ESTIMATED

#### Expanded Access Info
#### Last Update Post Date
**Date:** 2024-05-24

**Type:** ACTUAL

**Last Update Submit Date:** 2024-05-20

**Overall Status:** NOT_YET_RECRUITING

#### Primary Completion Date
**Date:** 2028-06

**Type:** ESTIMATED

#### Start Date
**Date:** 2024-06

**Type:** ESTIMATED

**Status Verified Date:** 2024-05

#### Study First Post Date
**Date:** 2024-05-24
**Type:** ACTUAL
**Study First Submit Date:** 2024-05-20
**Study First Submit QC Date:** 2024-05-20
### Sponsor Collaborators Module

#### Lead Sponsor

**Class:** OTHER

**Name:** True You Weight Loss

#### Responsible Party

**Type:** SPONSOR

### Oversight Module

**Is FDA Regulated Device:** False

**Is FDA Regulated Drug:** False

**Oversight Has DMC:** False

### Description Module

**Brief Summary:** The purpose of this study is to construct a multi-site, prospective registry to evaluate the clinical outcomes of patients who have undergone gastric fundus mucosal ablation at True You Weight Loss.

**Detailed Description:** Obesity is a chronic, progressive, multifactorial disease that contributes to increasing morbidity, mortality, and economic costs worldwide. The oxyntic mucosa of the gastric fundus is the principal site for the production of the orexigenic peptide hormone ghrelin. Ghrelin activates hunger-promoting pathways of the hypothalamus and opposes the satiety-promoting actions of other gastrointestinal peptides, leading to calorie-ingesting behaviors and weight gain. A method to reduce ghrelin production and decrease fundal compliance and capacity through mucosal devitalization may confer benefit to patients seeking treatment for obesity. This is a multi-site, prospective registry of patients who have elected to undergo Gastric Fundus Mucosal Ablation (GFMA) at a True You Weight Loss site in Cary, NC or Atlanta, GA. Study participants will consist of up to 200 adult patients of ages 18 to 65 years old who have elected to undergo GFMA at a True You Weight Loss site (Cary, NC or Atlanta, GA) prior to their involvement in the study. Participants that meet the criteria below will be deemed eligible for participation after consultation with the study investigator. Study participants will receive follow-up care according to standard of care practices, regardless of their involvement in the research study. Standard of care nutritional practice includes a comprehensive lifestyle program with long-term nutritional support and monitoring. Patient weights and adverse events will be collected at each visit. Adverse events will be communicated to medical team members in between dedicated visits. We aim to establish a multi-site, prospective registry to longitudinally describe GMFA in adults with obesity, including patient characteristics, weight loss, improvement in weight-related medical conditions, and adverse events.

### Conditions Module

**Conditions:**

- Obesity

**Keywords:**

- obesity

- ghrelin

- hunger

- ablation

- True You Weight Loss

- hunger hormone

- fundus

- fundus ablation

- fundic ablation

- GFMA

### Design Module

#### Design Info

**Observational Model:** COHORT

**Time Perspective:** PROSPECTIVE

#### Enrollment Info

**Count:** 200

**Type:** ESTIMATED

**Patient Registry:** True

**Study Type:** OBSERVATIONAL

**Target Duration:** 2 Years

### Outcomes Module

#### Primary Outcomes

**Description:** Measured percent change in total body weight over time following Gastric Fundus Mucosal Ablation. %TBWL = (pre-op weight - post op body weight) / (pre-op weight) \* 100 measured as a percentage.

**Measure:** Percent Change in Total Body Weight Loss (TBWL) from Baseline

**Time Frame:** 12 Months

#### Secondary Outcomes

**Description:** Measured percent change in total body weight over time following Gastric Fundus Mucosal Ablation. %TBWL = (pre-op weight - post op body weight) / (pre-op weight) \* 100 measured as a percentage.

**Measure:** Percent Change in Total Body Weight Loss (TBWL) from Baseline

**Time Frame:** 3 Months, 6 Months, 9 Months, 12 Months, 15 Months, 24 Months

**Description:** Measured excess weight loss percentage from baseline following Gastric Fundic Mucosal Ablation. %EWL = (pre-op weight - post op body weight) / (pre-op weight - ideal body weight) \* 100

Ideal Body Weight (IBW):

Males: IBW = 50 kg + 2.3 kg for each inch over 5 feet Females: IBW = 45.5 kg + 2.3 kg for each inch over 5 feet

**Measure:** Percent Excess Weight Loss from Baseline (EWL)

**Time Frame:** 3 Months, 6 Months, 9 Months, 12 Months, 15 Months, 24 Months

**Description:** Measured Body Mass Index (BMI) from baseline following Gastric Fundic Mucosal Ablation. Body Mass Index (BMI) = (Weight in kilograms) / ((Height in meters)\^2)

**Measure:** Change in Body Mass Index (BMI) from Baseline

**Time Frame:** 3 Months, 6 Months, 9 Months, 12 Months, 15 Months, 24 Months

### Eligibility Module

**Eligibility Criteria:** Inclusion Criteria:

1. Age ≥ 18 years and ≤ 65 years old
2. BMI ≥ 27 and ≤55 kg/m²
3. Willingness to comply with the substantial lifelong dietary restrictions required by the procedure.
4. Ability to give informed consent
5. Women of childbearing potential (i.e., not post-menopausal or surgically sterilized) must agree to use adequate birth control methods.
6. Those who plan to receive the gastric fundus mucosal ablation procedure at True You Weight Loss regardless of the research

Exclusion Criteria:

1. Patients that do not meet eligibility requirements for the study as per the Principal Investigator's standard selection criteria
2. Active psychological issues preventing participation in a life-style modification program as determined by a psychologist.
3. Patients who are pregnant or breast-feeding.
4. Eating disorders including night eating syndrome (NES), bulimia, binge eating disorder, or compulsive overeating.
5. Patients with previous or current tobacco use
6. Patients with prior gastric surgery (e.g., vertical sleeve gastrectomy, gastric bypass, hiatal hernia repair, Nissen fundoplication, adjustable gastric band).
7. Patients on therapeutic anticoagulation or antithrombotics that cannot be interrupted for at least 12 weeks following GFMA.
8. Patients who cannot commit to 12 weeks of post-GMFA pharmacologic ulcer prophylaxis
9. At the discretion of the PI for subject safety

**Maximum Age:** 65 Years

**Minimum Age:** 18 Years

**Sampling Method:** NON_PROBABILITY_SAMPLE

**Sex:** ALL

**Standard Ages:**

- ADULT

- OLDER_ADULT

**Study Population:** Study participants will consist of up to 200 adult patients of ages 18 to 65 years old who have elected to undergo Gastric Fundus Mucosal Ablation (GFMA) at a True You Weight Loss site (Cary, NC or Atlanta, GA) prior to their involvement in the study. Participants that meet the criteria below will be deemed eligible for participation after consultation with the study investigator. All eligibility criteria must be met at the time of enrollment.

### Contacts Locations Module

#### Central Contacts

**Contact 1:**

**Email:** Chase@trueyouweightloss.com

**Name:** Chase Wooley, BS

**Phone:** 919-336-4171

**Role:** CONTACT

**Contact 2:**

**Email:** Shannon@trueyouweightloss.com

**Name:** Shannon Casey, BS, MS

**Phone:** (919) 391-7843

**Role:** CONTACT

#### Locations

**Location 1:**

**City:** Atlanta

**Contacts:**

***Contact 1:***

- **Email:** Chase@trueyouweightloss.com

- **Name:** Chase Wooley, BS

- **Phone:** 919-336-4171

- **Role:** CONTACT

***Contact 2:***

- **Email:** Shannon@trueyouweightloss.com

- **Name:** Shannon Casey, BS, MS

- **Phone:** (919) 391-7843

- **Role:** CONTACT

***Contact 3:***

- **Name:** Christopher McGowan, MD, MSCR

- **Role:** PRINCIPAL_INVESTIGATOR

***Contact 4:***

- **Name:** Daniel Maselli, MD

- **Role:** PRINCIPAL_INVESTIGATOR

***Contact 5:***

- **Name:** Lauren Donnangelo, MD

- **Role:** PRINCIPAL_INVESTIGATOR

**Country:** United States

**Facility:** True You Weight Loss

**State:** Georgia

**Zip:** 30342

**Location 2:**

**City:** Cary

**Country:** United States

**Facility:** True You Weight Loss

**State:** North Carolina

**Zip:** 27513

### References Module

#### See Also Links

**Label:** Sponsor Website for more information

**URL:** http://www.trueyouweightloss.com

## Derived Section

### Condition Browse Module - Ancestors

- ID: D000001835

- Term: Body Weight

- ID: D000001836

- Term: Body Weight Changes

### Condition Browse Module - Browse Branches

- Abbrev: BC18

- Name: Nutritional and Metabolic Diseases

- Abbrev: BC23

- Name: Symptoms and General Pathology

- Abbrev: All

- Name: All Conditions

### Condition Browse Module - Browse Leaves

- ID: M12701

- Name: Obesity

- Relevance: LOW

- As Found: Unknown

- ID: M18102

- Name: Weight Loss

- Relevance: HIGH

- As Found: Weight Loss

- ID: M5114

- Name: Body Weight

- Relevance: LOW

- As Found: Unknown

- ID: M5115

- Name: Body Weight Changes

- Relevance: LOW

- As Found: Unknown

### Condition Browse Module - Meshes

- ID: D000015431

- Term: Weight Loss

### Intervention Browse Module - Browse Branches

- Abbrev: All

- Name: All Drugs and Chemicals

### Intervention Browse Module - Browse Leaves

- ID: M9789

- Name: Hormones

- Relevance: LOW

- As Found: Unknown

### Misc Info Module

- Version Holder: 2024-05-31
